COMMUNIQUÉS West-GlobeNewswire

KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

09/06/2017 - 06:58

PRESS RELEASE This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

NICOX : Issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to former Aciex shareholders following the US FDA's approval of ZERVIATE

09/06/2017 - 01:05

Press release This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Communiqué rectificatif: Emission et admission aux négociations sur le marché réglementé d'Euronext à Paris de 597.897 actions nouvelles attribuées aux anciens actionnaires d'Aciex suite à l'approb...

09/06/2017 - 00:05

Communiqué de presse This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for [...]

TARGOVAX ASA - SUCCESSFULLY COMPLETED PRIVATE PLACEMENT

08/06/2017 - 22:30

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR [...]

Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting

08/06/2017 - 22:30

Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month AMG 334 (erenumab) significantly reduced monthly [...]

Nicox: Emission et admission aux négociations sur le marché réglementé d'Euronext à Paris de 597 897 actions nouvelles attribuées aux anciens actionnaires d'Aciex suite à l'approbation du ZERVIATE

08/06/2017 - 20:00

Communiqué de presse Nicox annonce l'émission et l'admission aux négociations sur le marché réglementé d'Euronext à Paris de 597.897 actions nouvelles attribuées aux anciens actionnaires d'Aciex suite à l'approbation [...]

Nicox: Issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to existing Aciex shareholders following the US FDA's approval of ZERVIATE

08/06/2017 - 20:00

Press Release Nicox announces the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to existing Aciex shareholders following the US FDA's approval of the new drug [...]

Solon Eiendom ASA - Primary insider notification

08/06/2017 - 18:08

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 8 June 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan [...]

CROSSJECT : point d'activité

08/06/2017 - 18:00

Point d'activité Confirmation du calendrier des dépôts d'AMM Dijon, le 8 juin 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de médicaments combinés innovants [...]

CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social

08/06/2017 - 18:00

Information relative au nombre total de droits de vote et d'actions composant le capital social 8 juin 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de [...]

Eckert & Ziegler BEBIG: Paola Eckert-Palvarini élue membre du Conseil d'administration.

08/06/2017 - 15:30

Communiqué de presse INFORMATIONS RÉGLEMENTÉES Seneffe, 8 juin 2017. Lors de l'Assemblée générale annuelle qui s'est tenue aujourd'hui à Seneffe (Belgique), les actionnaires de Eckert & Ziegler BEBIG SA ont nommé [...]

The IPO of Silmäasema Oyj has been oversubscribed and the final subscription price is EUR 6.90 per share

08/06/2017 - 14:00

Stock Exchange Release 8 June 2017, at 3 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE OR JAPAN OR ANY [...]

HomeVi announces that PAI Partners has entered into exclusive negotiations with ICG and Yves Journel for the sale of a majority stake in the DomusVi group

08/06/2017 - 09:30

Suresnes, June 8th, 2017 - 9:30 am HomeVi S.A.S. ("HomeVi") today announced that its controlling shareholder, PAI Partners, has entered into exclusive negotiations with Intermediate Capital Group ("ICG") and Sagesse [...]

VALNEVA annonce la mise à disposition des documents préparatoires aux Assemblées d'actionnaires

08/06/2017 - 08:30

Valneva annonce la mise à disposition des documents préparatoires aux Assemblées d'actionnaires Lyon (France), 8 juin 2017 - Les actionnaires de la société Valneva SE (ci-après "Valneva" ou " le Groupe") sont invités à [...]

MDxHealth Launches CE-Marked SelectMDx IVD PCR Kit and UrNCollect Device

08/06/2017 - 07:00

NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION / FOR EX-US ONLY IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, June 08, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the launch in Europe and other [...]

MDxHealth lance le kit IVD PCR SelectMDx marqué CE et le dispositif UrNCollect

08/06/2017 - 07:00

COMMUNIQUE DE PRESSE / INFORMATION REGLEMENTAIRE / I NFORMATION PRIVILEGIEE / POUR EX-US SEULEMENT IRVINE, CA et HERSTAL, BELGIQUE - 07:00 CEST, le 08 juin 2017 - MDxHealth SA (Euronext: MDXH.BR) a annoncé aujourd'hui [...]

Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD

08/06/2017 - 07:00

ALLSCHWIL, SWITZERLAND - 08 June 2017 - Actelion Ltd (SIX: ATLN) today provided an update on the Phase III program IMPACT to investigate the efficacy and safety of Actelion's novel anti-infective cadazolid versus [...]

Bone Therapeutics SA : completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

08/06/2017 - 07:00

Regulated information Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB ® Positive results could lead to further validation of Company's bone-cell [...]

Bone Therapeutics SA : finalise le recrutement des patients pour l'analyse intermédiaire de l'étude de Phase III avec PREOB® dans l'ostéonécrose

08/06/2017 - 07:00

Information réglementée Bone Therapeutics finalise le recrutement des patients pour l'analyse intermédiaire de l'étude de Phase III avec PREOB ® dans l'ostéonécrose Des résultats positifs permettraient de poursuivre la [...]